-

Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures. The company provides complete solutions for gel permeation chromatography (GPC) and size exclusion chromatography (SEC) used in applications to determine the molecular weight and size distribution of macromolecules.

The acquisition broadens and extends Agilent’s product portfolio and customer offerings, particularly in the chemical and biopharmaceutical industries for the analysis of natural and synthetic polymers such as nucleic acids, proteins, monoclonal antibodies, polysaccharides, and synthetic plastic.

“We’re extremely pleased to have the PSS team join Agilent to help us expand our leadership in liquid chromatography and the GPC/SEC market,” said Jacob Thaysen, president, Agilent Life Sciences and Applied Markets Group. “The advanced PSS hardware, software, columns and reference materials we’re adding to our portfolio will enhance our offerings and ensure we deliver the broad spectrum of LC equipment, GPC/SEC analytics and software our customers value.”

By acquiring PSS, Agilent will also add a key software component to complement its lineup of GPC/SEC products. In addition, Agilent will be able to use its global presence to expand the use of PSS products and expertise more widely. Agilent customers in the chemical, biopharmaceutical and other key segments will now also be able to take advantage of PSS technology more broadly because of Agilent’s strong global presence in those markets.

“This is a very strategic move for PSS and Agilent,” said Thorsten Hofe, managing director at PSS. “Together we can provide our customers a full range of GPC and LC products and extend the reach of PSS products into new, fast-growing markets. It’s an exciting time for the PSS team.”

Founded in 1985, PSS is privately held and is based in Mainz, Germany, with additional operations in Amherst, Mass. Financial terms of Agilent’s acquisition of PSS were not disclosed.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent Technologies has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization.
Release Versions

Contacts

Media Contact:
Sarah Litton
669-255-7696
sarah.litton@agilent.com

Investor Contact:
Parmeet Ahuja
408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom